Enlivex to Present 3-Month Topline Data from Moderate/Severe Knee Osteoarthritis Trial

Enlivex Therapeutics will host a webinar on August 18 to present 3-month topline results from its Phase IIa trial of Allocetra in patients with moderate to severe knee osteoarthritis. The trial aims to evaluate safety and efficacy of Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Osteoarthritis affects over 300 million people worldwide and symptomatic knee osteoarthritis is particularly prevalent.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) is set to host a webinar on August 18, 2025, at 8:00 AM ET to present 3-month topline results from its Phase IIa trial of Allocetra™ for moderate to severe knee osteoarthritis. The webinar will feature a detailed analysis of the 3-month data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.

The trial, which is a double-blind, randomized, placebo-controlled study, enrolled 134 patients who have completed the 3-month follow-up period. The primary endpoints measure joint pain and function versus placebo at 3, 6, and 12 months post-injection. The trial aims to assess both safety and efficacy of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.

Knee osteoarthritis is a prevalent condition, affecting over 32.5 million Americans and 300 million people worldwide. The first stage of the trial, a Phase I open-label dose-escalation study, was completed to evaluate safety and tolerability and to determine optimal dosing. The ongoing Phase IIa stage is a double-blind, randomized, placebo-controlled trial, assessing both safety and efficacy.

The webinar will provide insights into the potential benefits of Allocetra™ in treating knee osteoarthritis, a condition that significantly impacts the quality of life for millions of people. Investors and stakeholders are encouraged to register for the webinar to gain a deeper understanding of the trial's progress and the potential implications for the company's pipeline.

References:
[1] https://www.stocktitan.net/news/ENLV/enlivex-to-present-3-month-topline-data-from-phase-i-ia-moderate-dstvjf0z0oko.html